BenevolentAI Results Presentation Deck | Slidebook.io

BenevolentAI Results Presentation Deck

March 2023, 38 slides

preliminary results for the year ended march benevolent | BenevolentAI

disclaimer forward looking statements this document may contain forward looking statements forward looking statements are statements that are not historical facts and may be by words such as plans targets aims believes expects anticipates intends estimates will may should and similar expressions forward looking statements include statements regarding objectives goals strategies outlook and growth prospects future plans events or performance and potential for future growth economic outlook and industry trends developments in markets the impact of regulatory initiatives and or the strength of competitors these forward looking statements at the time made beliefs intentions and current targets aims forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future the forward looking statements in this release are based upon various assumptions based on without limitation management examination of historical operating trends data contained in records and third party data although believes that these assumptions were reasonable when made these assumptions are inherently subject to cant known and unknown risks uncertainties contingencies and other important factors which are cult or impossible to predict and are beyond control forward looking statements are not guarantees of future performance and such risks uncertainties contingencies and other important factors could cause the actual outcomes and the results of operations condition and liquidity of or the industry to differ materially from those results expressed or implied by such forward looking statements the forward looking statements speak only as of the date of this release no representation or warranty is made that any of these forward looking statements or forecasts will come to pass or that any forecast result will be achieved | BenevolentAI

the benevolent platform business model shields agenda preliminary results for the year ended nick pipeline review outlook shields | BenevolentAI

a year of solid progress and growth for enhanced the benevolent platform progressed our pipeline and delivered in commercial collaboration with ben completed phase study and expect top line data in ben submitted in expect to initiate a phase i clinical trial in ben declared as a clinical candidate in with preparation for enabling studies ongoing portfolio into new disease areas year collaboration expansion with additional novel targets selected for in house assets transitioned into lead new in house drug programmes generated using the benevolent platform approval of covid treatment by | BenevolentAI

is a leading enabled drug discovery development company with a platform generated pipeline discovery development industry leading platform uncovers novel biology across diseases and drug modalities portfolio of in class and best in class programs discovered using our proprietary platform discovery preclinical clinical expansive knowledge graph with multimodal data foundations disease and drug modality agnostic generate predictions with the aim to increase the probability of success asset in phase assets in platform generated drug programmes enabled | BenevolentAI

powerful data foundations generate a view of disease biology experiments assay data binding comparison screens clinical trial genes proteins transcripts variants biological systems cellular component molecular function biological process mechanism pathways literature literature patent literature regulatory documents diseases symptoms molecules organic compounds preclinical candidates approved drugs antibodies other pharmacology multimodal approach combines over data sources to provide a holistic view of disease biology our probability of clinical success by integrating disease traits genetics and data to generate target predictions breaks down silos across therapeutic areas to connect shared mechanisms across disease provides a proprietary integrated view of data that supports discovery and decision making | BenevolentAI

the benevolent platform empowers scientists with industry leading drug discovery comprehensive data foundations biology hypothesis driven target identification proprietary models reason across modal data to discover novel targets enables scientists to assess select only the most promising targets to take into wet lab experiments surfaces evidence to support higher con decisions data fed back into the knowledge graph to enhance future predictions | BenevolentAI

our business model unlocks multiple routes to value creation discovery tools owned pipeline platform generated assets in house development licensing platform generated assets out licensed at end phase i or end platform collaborations economic bene platform validation data generated enriches the benevolent non commercial collaborations platform validation data generated enriches the benevolent flexible | BenevolentAI

preliminary results for the year ended nick | BenevolentAI

financial highlights revenue drug discovery product technology a business operations bus underlying expenses related to share based payments other income operating loss revenue increase across collaboration with additional novel targets in chronic kidney disease and idiopathic pulmonary spend increase driven by advancing pipeline into later stages of development particularly ben adaptive phase i and ben ling enablement in net named programmes added into pipeline during the year in pence weighted average ordinary shares outstanding in millions spend increase increased expected to plateau bus spend driven predominantly by listing status and expected to maintain at this level | BenevolentAI

reported to operating loss adjustments for a direct transaction costs a transaction related listing service expense a transaction related employee related expense a impairment of assets a transaction related stamp duty revaluation of investments group operating loss reported operating loss driven by non recurring costs of business combination non cash exceptional costs related to acceleration of share based payments also incurred from business combination and set to reduce beyond non cash listing service expenses cost of share issuance to as part of business combination net of assets acquired before pipe and backstop | BenevolentAI

cash focused upon drug and platform development operating loss depreciation foreign exchange other employee related expense cash from changes in working capital cash expended from underlying operating activities opening cash cash equivalents and short term deposits closing cash cash equivalents and short term deposits property related leases gain from holdings gain from holdings charge from operational non transaction related equity awards removed from the no cash impact largely driven by increase in tax credit receivable as well as decrease in employer related tax provision year end cash position of at the top end of our stated guidance flows | BenevolentAI

cash runway to providing capital for key value in points cash runway capital allocation cash at cash burn of before working capital movements cash runway guidance assumes no future capital from licensing or collaboration agreements multiple assets at or close to key value in points fund phase i trial for ben in ulcerative colitis and commencement of phase trial in fund enabling work for ben and begin phase i trial in in progress balance of pipeline as well as fund enabling work of novel als asset to complete in continuous enhancement of the benevolent platform to support further collaborations business operations to support group activities sufficient inflection | BenevolentAI

pipeline review | BenevolentAI

robust pipeline entirely generated by the benevolent platform highlights all pipeline programmes generated using the benevolent platform ben phase read out ben novel target with zero prior linkage to delivered drug candidate within years from initiation starting phase year target collaboration expanded in to include systemic lupus heart failure | BenevolentAI

ben for atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion by ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting mediated dermal in using our molecular design we were able to design a inhibitor equipotent against the receptors atopic dermatitis treatment paradigm mild moderate severe ben will target mild moderate and severe patients addressing unmet need as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment i | BenevolentAI

ben phase clinical study designed to demonstrate in mild moderate atopic dermatitis study design safety efficacy study efficacy outcomes recruitment completed end of patients for ben vehicle patients inclusion criteria mild moderate viga itch atopic dermatitis affecting of treatable skin years dosing day medication washout followed by day placebo run in prior to dosing ben or placebo vehicle applied twice daily to treatable skin up to days on treatment powered itch change from in the pruritus worst itch over hours and current itch time to itch reduction fraction of patients achieving itch reduction in change from in score fraction of patients achieving improvement in score change from in affected by in treated area change from in viga quality of life change from in poem change from in change from in change from in sleep | BenevolentAI

ben phase study recruitment completed phase clinical study design day wash out from any existing medication day placebo run in day bid dosing on affected skin a maximum of placebo active moderate mild patient ratio total of patients active placebo day final safety assessment current status achieved end patients moderate and mild completed march anticipated end march our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved | BenevolentAI

ben ulcerative colitis affects us population million patients in forecast market by a chronic lifelong disease that causes in and ulceration of the inner lining of the colon and rectum of patients are mild moderate of patients are moderate severe and of patients are severe fulminant of moderate severe patients do not respond to anti main treatment paradigm safety treatments have many side effects from steroids to anti and inhibitors black box warnings high unmet need for an alternative oral small molecule treatment option with improved safety pro and in treatment of refractory patients ben oral peripherally restricted inhibitor under development as a in class treatment for refractory was by our platform as an entirely novel target for the treatment of using our molecular design we designed a best in class peripherally restricted inhibitor ben ben is expected to provide an disease modifying oral treatment for ben will target moderate and severe patients meeting the unmet need left by existing therapies including patients refractory to anti or other improved safety and tolerability pro compared to competitors aiming to use a precision medicine approach to target key responder patient cohorts and avoid the safety risks associated with ineffective therapies | BenevolentAI

ben potent activity in colon biopsies cross donor response summary inhibition release mean inhibition from donors fens | BenevolentAI

ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in delivered drug candidate within years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI

outlook shields | BenevolentAI

with the world attention on applications that deliver real world impact we are strongly positioned to on this moment with our substantial portfolio of platform generated drugs our work with big and research collaborators and our continued investment in state of the art technology we are showing every day how can be used to unlock the next wave of innovation shields poised for growth multiple value in points expected ben top line results of the phase clinical trial expected in out license in subject to results ben initiate the phase i study in ben submit the in continued investment in state of the art technology aim to sign additional commercial collaboration commence enabling studies for at least one additional asset continue to progress pipeline assets to value in points | BenevolentAI

benevolent benevolent hello benevolent | BenevolentAI

appendix | BenevolentAI

world class team board of industry luminaries we build tech in the service of science combines deep across drug discovery development bus world class scientists technologists drug discovery tech | BenevolentAI

proven to enhance drug discovery disease agnostic modality agnostic built for scale we can work on any therapeutic area due to the breadth and diversity of our data foundations the benevolent platform can be applied to antibody and biologic targets in addition to small molecule targets our scalable and versatile platform can support multiple in house drug programmes and commercial collaborations accelerates discovery by combining our platform and wet lab facilities we accelerate discovery and reduce discovery and development identifies novel targets our predictive tools can surface targets that have never been considered for a disease before potential to increase probability of success by building higher con hypotheses in the stages of drug discovery we aim to reduce costly failures down the line | BenevolentAI

subject to positive date the asset will then be ready for phase i studies in poised for growth multiple value in points ben data expected ben out licensing internal pipeline depth and progression ben begin phase i study ben submit clinical trial application expect to add names drug programmes to portfolio ben phase i data package phase to follow shortly after ben initiate phase i study collaboration other platform collaborations aim to progress stage drug candidates every year potential new targets added for and heart failure prior targets for and for advancing discussions with a number of parties ongoing inflection | BenevolentAI

atopic dermatitis ben pan inhibition rationale potentiates stimulated cell in responses and synergistically enhances cell receptor induced production by cells mast cells within skin lesions express high levels of compared to normal controls skin resident express elevated levels of together with and and functionally respond to inhibit and increase chemotactic index levels in skin dramatically increase in response to in stimuli produced by is a major mediator of cutaneous increased in the skin sensitizes primary a contributing to peripheral itch sensitization and chronic pruritus involved in the in activation of mast cells and | BenevolentAI

ben excellent skin penetration experimental evidence supports high exposure in human skin at free and low exposure in blood with proposed clinical ointment strength ben ointment bid exceeds the exposure needed for inhibition in both epidermis upper dermis and lower dermis even at human in in in in free plasma levels below enabling tox package rat and pig topical safety margins fold for and fold for to dose limited a | BenevolentAI

we expect ben to provide both symptomatic relief and to reverse disease progression in atopic dermatitis ben is highly selective for receptors with potencies in the low range for and ben dose dependently inhibits release of in and and in human peripheral blood mononuclear cells stimulated with an in cell stimulus anti ben inhibition of human primary cell activation ben inhibits the release of gene related peptide a mediator of itch sensory nerve and neurogenic in in dorsal root ganglion isolated from adult rats and stimulated with ben series reduced mouse ear in following administration of reducing expression of and ben demonstrates excellent tolerability and safety margins in enabling toxicology studies inhibition of sensory neuron activation reduction in mouse ear in | BenevolentAI

ben phase safety and tolerability study successfully completed phase double blind placebo controlled in patient two part clinical study phase first in human dose phase completed mild moderate patients years per cohort ben placebo safety tolerability adaptive multiple ascending dose cohort design includes imaging to evaluate human skin phase successfully completed safety and tolerability arm adaptive design for phase of the clinical study | BenevolentAI

ben indicative data from phase caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days mean change from affected in treated areas day bid | BenevolentAI

ben a novel target for data support the rationale for as a novel target for regulates signal transduction by is in derived colon and colonic mucosa samples whilst which makes is down regulated reduced levels of correlate with increased in colonic mucosa is in and its expression inversely correlates to disease severity is well studied in disorders but not in in with zero linkage to demonstrates restricted expression in peripheral tissue reduces the safety liability of targeted inhibition degrades differential expression of a and normal low basal expression highest levels in brain low basal soluble levels except in colon and intestine | BenevolentAI

inhibition potential to mechanisms in inhibition camp reduced in release from intestinal epithelia via reduced tissue resident macrophage activation improved assembly via mediated improved mucus homeostasis via phosphorylation of intestinal reduced intestinal in improved barrier integrity | BenevolentAI

strategic validation successful collaboration with year target collaboration is delivering multiple novel targets for complex diseases with high unmet need separate data environment established to integrate data into a bespoke knowledge graph and teams working in close collaboration to explore identify and validate targets deal structure of license fee milestone payments and downstream royalties data generated via the collaboration enriches the benevolent platform five novel targets selected for portfolio to date initial deal focussed on chronic kidney disease idiopathic pulmonary fibrosis year collaboration expansion to include heart failure systemic lupus | BenevolentAI

using our platform for societal bene a covid treatment now approved for use by the non commercial collaboration rapid as a treatment in just hours published research in the lancet in novel our technology and work a previously unknown antiviral mechanism effective barrier trial showed reduces mortality by in patients and by in ventilated or patients focused on dengue fever a major burden aims to deliver biological targets and drug candidates experimental validation in progress assays approved the to treat covid in may after granting in led to equity investment from benefit lilt | BenevolentAI

of companies in hit target companies can be characterized across two key dimensions original technology focus and drug discovery approach target high complexity through biology many layers of knowledge needed and many areas where research is not yet complete hit high computational complexity figure analysis listed companies only companies also active in the space through internal development and or collaborations hypothesis driven involves a data driven hypothesis led approach to therapeutic target cation non hypothesis driven leverages technology to identify solutions without conditions to target at the outset | BenevolentAI

See More

BenevolentAI

Results Presentation Decks

Biotechnology Decks

Healthcare Decks

Explore Topics

Drug discovery

Clinical trial

Drug candidate

Clinical development

Recent decks by BenevolentAI

Investor Presentation

September 2024

Results

March 2024

Investor Conference

January 2024

Investor Presentation

May 2023

See all presentations by BenevolentAI (11 decks)

Related decks

Bionomics

IPO

December 2021

MindMed

Investor Presentation

June 2023

Valneva

IPO

April 2021

Absci

Investor Presentation

July 2023

MaxCyte

Results

November 2023

Absci

Investor Presentation

October 2022

Exscientia

Investor Presentation

March 2024

Absci

Investor Presentation

May 2022

Recent decks by BenevolentAI

See all presentations (11 decks)

Investor Presentation

September 2024

Results

March 2024

Investor Conference

January 2024

Investor Presentation

May 2023

Related decks

Bionomics

IPO

December 2021

MindMed

Investor Presentation

June 2023

Valneva

IPO

April 2021

Absci

Investor Presentation

July 2023

MaxCyte

Results

November 2023

Absci

Investor Presentation

October 2022

Exscientia

Investor Presentation

March 2024

Absci

Investor Presentation

May 2022

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Investment Banking

Explore

Presentation Collections

Slide Collections

Company

© 2021-2024 Slidebook.io